Response Genetics announces direct offering, shares rise


Shares of Response Genetics (RGDX +9.3%) are enjoying a strong session.

In a regulatory filing (8-K), the company said it has entered into an agreement with institutional investors for the sale of 902,835 shares of common stock at $2.05/share.

Gross proceeds to the company are expected to be ~$1.9M and will be used to "expedite the integration of the recently acquired proprietary FDA-cleared and Medicare-reimbursed Tissue of Origin test." (PR)

More on the acquisition here

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs